Maximus Vs Hone Health

Maximus and Hone Health both raise testosterone, and both do it through a telehealth clinician with medication shipped to your door. The mechanisms are opposites. Maximus centers on enclomiphene, which prompts your own body to make more testosterone and typically preserves fertility. Hone Health supplies testosterone from outside the body, which typically suppresses natural production while you are on it. Price separates them too — Maximus starts higher and bills labs separately — but the mechanism is the decision most men are actually making.

What each platform actually is

Maximus

Maximus is a telehealth hormone platform for men built around enclomiphene. A physician reviews your labs and history, prescribes the protocol, and remains available for dose adjustment; medication ships where prescribed. The enclomiphene itself is bundled into the monthly membership in most protocols, so the drug sits inside the price rather than beside it. Lab work is the piece that is not bundled — the initial assessment and every follow-up panel are billed separately and collected at a partner lab, which means a venous draw is part of the routine. Traditional TRT is available where clinically indicated, priced on top. The panel is hormone-focused rather than broad, and Maximus does not run GLP-1, peptide, or general longevity programs.

Hone Health

Hone Health is a telehealth membership built around traditional testosterone replacement, and the platform owns the whole loop. A finger-prick kit arrives at your home, you mail the sample back, results return in 5–7 days, a clinician judges candidacy, and any prescribed medication is dispensed through a partner pharmacy. TRT patients retest quarterly on a fixed schedule. What you are buying is exogenous testosterone — the hormone supplied from outside — which is the mechanical opposite of what Maximus centers on. The base panel is hormone-focused and limited, so metabolic, thyroid, and inflammatory markers are not part of the standard product, and the prescription pathway is TRT-first with limited peptide options.

Side by side on the standard rubric

The same nine criteria applied to every platform page. The columns split hardest on prescription pathway, draw type, and which costs sit outside the membership.

The fertility preservation question

Exogenous TRT typically suppresses the brain's LH and FSH signaling to the testes, which reduces or shuts down natural testosterone production and typically impairs fertility. Enclomiphene works by blocking estrogen feedback in the brain, prompting more LH and FSH — which stimulates the testes to produce more testosterone on their own. Sperm production is preserved. For men who want higher testosterone but also want to father children, that trade-off is decisive.

The corollary is less discussed. A protocol that works through your own axis depends on that axis being able to respond, so the first follow-up panel on Maximus is doing diagnostic work, not just confirming a dose. A protocol that replaces the hormone directly does not have that dependency, which is part of why traditional TRT is the simpler product to deliver at a low price.

What each actually costs

Maximus quotes a membership, not a total. Programs run $150–$300 a month depending on protocol, which is $1,800–$3,600 across twelve months, and the initial assessment adds $200–$400 on top of that. Enclomiphene is included in most protocols, so the medication does not appear as a separate monthly line — but lab work does. Follow-up panels run $100–$300 each, and if traditional TRT is prescribed alongside or instead, that adds $50–$150 a month. Year two loses the one-time initial assessment, landing near $1,600–$3,200 plus whatever panels the protocol calls for.

Hone Health splits on one decision: whether a clinician prescribes. Testing and membership alone sit near $45 a month, so a year of testing without treatment is around $540. An active protocol including medication runs $150–$220+ a month, or $1,800–$2,640 for the year. Nothing here is a one-time fee, so year two mirrors year one at whichever tier you ended up on. Lab work is not a separate invoice because the finger-prick kit is the testing, which is why the annual figure is easier to state in advance than the Maximus one.

Where Maximus leads

• Fertility-preserving mechanism. Enclomiphene raises testosterone by increasing LH and FSH signaling, so testicular function and sperm production continue during treatment.
• Medication inside the membership. Enclomiphene is bundled into the monthly price in most protocols, so the drug is not a separately fluctuating line.
• Two prescribing routes under one physician. Enclomiphene, traditional TRT, or a combination can be prescribed as labs and goals dictate, without changing platform.
• Venous collection at a partner lab. A drawn sample supports a wider ordered panel than a home hormone kit is designed to collect.
• Access to a route most platforms skip. Enclomiphene is not offered by most telehealth testosterone providers, so the option itself is the product.

Where Hone Health leads

• Collection at home. No appointment and no draw site — the finger-prick kit is collected at your kitchen table and mailed, with results back in 5–7 days.
• Lowest entry cost. Around $45 a month covers the hormone test and a clinician's read on candidacy before any treatment commitment.
• Fewer moving parts in the bill. Membership and testing are a single rate with medication as the only variable, rather than lab work arriving as its own invoice.
• A fixed testing rhythm. TRT patients retest quarterly on a set schedule, so the year's testing calendar is known at signup.
• One platform end to end. Test, clinician review, prescription, and shipped medication all sit inside a single flow with no order to carry elsewhere.

Trade-offs to weigh

Maximus trade-offs

• Labs are outside the price. Initial and follow-up panels run $100–$300 each and are billed separately, so the $1,800–$3,600+ membership figure is not the all-in number.
• Higher monthly floor. Programs start at $150 a month before any lab work, which is a different commitment level from a sub-$50 entry tier.
• Narrow scope. Metabolic, thyroid, and inflammation work sits outside the core product, as do GLP-1 and peptide protocols.
• Requires a draw site. Baseline and follow-up panels mean venous collection at a partner lab, on their hours, rather than a kit you post back.

Hone Health trade-offs

• The mechanism suppresses your own production. Exogenous TRT typically reduces LH and FSH signaling, and fertility is typically impaired for as long as you are on it.
• Quarterly retesting. Roughly thirteen weeks pass between panels, so a dose that needs correcting runs a full quarter before the next data point arrives.
• Medication is priced on top. The membership rate does not include TRT; $150–$220+ a month is what the active protocol actually costs.
• Hormone-focused panel. Non-hormonal contributors to the same symptoms are not measured in the standard product, so they are not ruled out before treatment starts.

Who should pick each

Pick Maximus if: you want testosterone higher and you are not finished having children — or you are genuinely undecided, which is the case the enclomiphene route exists for. You can carry $150–$300 a month plus separate lab bills, you will make trips to a draw site, and you want a physician who can prescribe either mechanism so the protocol can change when your labs or your plans do.

Pick Hone Health if: fertility is settled for you — done having children, or it is not part of the plan — and straightforward traditional TRT is what you are after. You want the lowest entry price in the category, a sample you collect at home, and a fixed quarterly testing rhythm. You want one rate covering testing and clinician access, with medication as the only line that moves.

Who should pick neither

Both platforms treat a testosterone number as the target. If yours has not been confirmed on a morning draw, neither is the right first purchase. Low testosterone is also downstream of other things in a meaningful share of cases — untreated sleep apnea, substantial weight gain, chronic under-recovery, and some medications all push it down. Treating the hormone without addressing the driver can mean a long-term prescription for something that was reversible.

• Doctor-led options compared — Fountain Life, Lifeforce, Marek Health, and Opt Health each bundle a clinician with a broader panel than either hormone-first platform here.
• An in-network endocrinology referral, if a first reading has already come back low. A specialist works up the cause rather than the number, and that route is often covered in a way telehealth memberships are not.
• Best TRT clinics 2026 — the wider field, including in-person clinics, if you want a physician you can sit across from.
• Hone Health vs Marek Health — if peptides or ancillaries are part of what you want managed, neither platform on this page covers that.

Can you use both?

Simultaneously, no. Both prescribe into the same signaling axis from opposite ends, and running two prescribers against one endocrine system is a clinical problem rather than a budgeting one. The combined annual cost would land roughly between $2,340 and $6,240 before Maximus lab work, and a large part of that pays twice for the same hormone panel. There is no version of the stack where the second membership measures something the first cannot.

Sequentially there is one defensible case, and it is specific: a man on Hone Health's traditional TRT who decides he wants children. Moving to an enclomiphene protocol means coming off exogenous testosterone and asking a suppressed axis to restart, and that transition is worth keeping both relationships live through — the existing prescriber to manage the exit, the new one to run the baseline and start the new protocol. Outside that handover, keep one platform. Going the other direction, from Maximus to Hone Health, is simpler and needs no overlap at all.

What the rubric does not capture

The rubric shows both platforms bundle a telehealth clinician. What it cannot show is that the clinician is doing a different job on each. On Hone Health, the follow-up panel confirms a level: you supplied the hormone, the question is how much. On Maximus, the follow-up panel asks whether your own system responded to being prompted, which is a diagnostic question with a less predictable answer. That is why the first retest carries more weight on Maximus, and why the enclomiphene route is less suited to a set-and-forget membership.

Cancellation is the other asymmetry, and no table row holds it. Stopping enclomiphene withdraws a stimulus from an axis that was never shut down. Stopping traditional TRT means restarting production that has been suppressed the whole time you were treated, which needs a physician-managed plan and a timeline. Anyone weighing these two on monthly price should weigh the exit as well, because it is the part of the decision that is hardest to reverse and the part neither platform's pricing page describes.

Month six also feels different on each. On Hone Health, a settled dose turns the product into a repeating prescription plus a quarterly kit, and the question becomes whether the membership still earns its place beside the medication. On Maximus, month six is where the separate lab bills accumulate into a number nobody quoted at signup, and where the value depends on whether the protocol is still being adjusted. Both are also built around the same narrow user — a man treating a hormone — so anyone whose symptoms turn out to be metabolic, thyroid, or sleep-driven will find the product has nowhere to go with that.

Related

• Full Maximus review
• Maximus cost breakdown
• Full Hone Health review
• Is Maximus worth it?
• Is Hone Health worth it?
• Opt Health vs Maximus
• Opt Health vs Hone Health
• Best TRT clinics 2026
• All doctor-led options compared